Torrent Pharmaceutical Ltd, the Ahmedabad-based pharma company, has received an approval status from the United Sates Food and Drug Agency (US FDA) for its API and formulation manufacturing facilities at Chhatral, in Ahmedabad.

The company's manufacturing plant at Chhatral has a capacity to manufacture approximately 6,000 million tablets, capsules and vials and 15000 kgs of Bulk drugs and APIs. Authorities from regulated markets have already approved the same facility.

The company has submitted 5 ANDAs and 3 DMFs for the US FDA approval. It has around 5DMFs and 26 ANDAs in pipeline. Torrent is moving ahead towards the US market.

Torrent has significant presence in more than 50 countries. It continues to be at the forefront of the Indian pharmaceutical industry through research, innovation and break through discoveries in the therapeutics areas of Diabetology, Cardiovascular, Central Nervous System, Gastro-Intestinal, Anti-infective and pain management.

The company's R&D centre employs over 500 scientists in the areas of drug discovery and management. Currently, it has seven discovery projects in pipeline. It has also filed 219 patents for NCEs in all major markets worldwide, of which 123 patents have been granted.